Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price fell 5.7% during trading on Tuesday . The stock traded as low as $21.88 and last traded at $21.70. 263,869 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 300,792 shares. The stock had previously closed at $23.00.
Analysts Set New Price Targets
Several brokerages recently issued reports on ELVN. Jones Trading cut their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 price objective for the company. Finally, Robert W. Baird increased their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $41.20.
Check Out Our Latest Stock Report on Enliven Therapeutics
Enliven Therapeutics Price Performance
The company has a fifty day simple moving average of $19.93 and a two-hundred day simple moving average of $20.28. The company has a market capitalization of $1.12 billion, a P/E ratio of -11.84 and a beta of 0.83.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Insider Buying and Selling at Enliven Therapeutics
In other news, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the transaction, the chief executive officer directly owned 952,892 shares in the company, valued at approximately $21,135,144.56. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total value of $135,606.78. Following the completion of the transaction, the chief operating officer owned 303,309 shares in the company, valued at $6,169,305.06. The trade was a 2.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 96,111 shares of company stock worth $1,891,776 over the last three months. Corporate insiders own 25.90% of the company's stock.
Hedge Funds Weigh In On Enliven Therapeutics
A number of institutional investors have recently made changes to their positions in ELVN. Polar Capital Holdings Plc increased its stake in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the period. Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics in the fourth quarter worth about $15,106,000. Janus Henderson Group PLC grew its position in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after buying an additional 290,153 shares in the last quarter. FMR LLC grew its position in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after buying an additional 199,692 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its position in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after buying an additional 135,969 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
